Zai Lab
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Zai Lab (ZLAB) | 2.36B | -11.68 | 4.20 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 63.1% below Morningstar's fair value estimate.
Fair value
At face value, Zai Lab Ltd looks inexpensive, following a substantial price decline over the past year. To account for the risk of a possible value trap, we have capped its rating at 3 stars. The stock currently trades at a 28% discount to our quantitative fair value estimate of $34.31 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The firm's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 4.7, which falls in the bottom 45% compared with peers globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be undervalued.
The company's liquidity is an additional encouraging factor. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. The firm's median trading volume over the past 60 days, a core component of liquidity, falls in the top 20% compared with global peers. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. This characteristic further promotes our favorable price/fair value ratio.
Economic moat
The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Zai Lab discussion 0 comments